Literature DB >> 29220301

Soft Tissue and Uterine Leiomyosarcoma.

Suzanne George1, César Serrano1, Martee L Hensley1, Isabelle Ray-Coquard1.   

Abstract

Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma in adults and can occur in almost any part of the body. Uterine leiomyosarcoma is the most common subtype of uterine sarcoma. Increased awareness of this unique histology has allowed for the development of drugs that are specific to LMS and has begun to shed light on the similarities and possible unique aspects of soft tissue and uterine LMS. In this review, we summarize the current understanding of the epidemiology, diagnosis, genomics, and treatment options for LMS.

Entities:  

Mesh：

Year:  2017        PMID： 29220301      PMCID： PMC5759317          DOI： 10.1200/JCO.2017.75.9845

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  55 in total

1.  The role of pulmonary metastasectomy in soft tissue sarcoma.

Authors:  Larissa K F Temple; Murray F Brennan
Journal:  Semin Thorac Cardiovasc Surg       Date:  2002-01

2.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.

Authors:  P W Pisters; D H Leung; J Woodruff; W Shi; M F Brennan
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

3.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Authors:  George D Demetri; Margaret von Mehren; Robin L Jones; Martee L Hensley; Scott M Schuetze; Arthur Staddon; Mohammed Milhem; Anthony Elias; Kristen Ganjoo; Hussein Tawbi; Brian A Van Tine; Alexander Spira; Andrew Dean; Nushmia Z Khokhar; Youn Choi Park; Roland E Knoblauch; Trilok V Parekh; Robert G Maki; Shreyaskumar R Patel
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

4.  Dedifferentiated leiomyosarcoma: clinicopathological analysis of 18 cases.

Authors:  Eleanor Chen; Fionnuala O'Connell; Christopher D M Fletcher
Journal:  Histopathology       Date:  2011-12       Impact factor: 5.087

Review 5.  The role of surgical margin status in retroperitoneal sarcoma.

Authors:  Daniel A Anaya; Dina C Lev; Raphael E Pollock
Journal:  J Surg Oncol       Date:  2008-12-15       Impact factor: 3.454

6.  Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.

Authors:  S W Bell; R L Kempson; M R Hendrickson
Journal:  Am J Surg Pathol       Date:  1994-06       Impact factor: 6.394

7.  Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.

Authors:  Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Robert A Soslow; Mario M Leitao; Carol Aghajanian; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2009-11-24       Impact factor: 5.482

8.  Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Authors:  Javier Martin-Broto; Antonio López Pousa; Ramón de Las Peñas; Xavier García Del Muro; Antonio Gutierrez; Javier Martinez-Trufero; Josefina Cruz; Rosa Alvarez; Ricardo Cubedo; Andrés Redondo; Joan Maurel; Juan A Carrasco; José A López-Martin; Ángeles Sala; José Andrés Meana; Rafael Ramos; Jordi Martinez-Serra; José A Lopez-Guerrero; Isabel Sevilla; Carmen Balaña; Ángeles Vaz; Ana De Juan; Regina Alemany; Andrés Poveda
Journal:  J Clin Oncol       Date:  2016-05-16       Impact factor: 44.544

Review 9.  Clinical aspects of postirradiation sarcomas.

Authors:  E Robinson; A I Neugut; P Wylie
Journal:  J Natl Cancer Inst       Date:  1988-04-20       Impact factor: 13.506

10.  A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.

Authors:  Beatrice Seddon; Michelle Scurr; Robin L Jones; Zoe Wood; Cerys Propert-Lewis; Cyril Fisher; Adrienne Flanagan; Jonanthan Sunkersing; Roger A'Hern; Jeremy Whelan; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2015-05-16
View more
  38 in total

1.  Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Authors:  Rebecca C Arend; Michael D Toboni; Allison M Montgomery; Robert A Burger; Alexander B Olawaiye; Bradley J Monk; Thomas J Herzog
Journal:  Oncologist       Date:  2018-08-23

2.  Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes.

Authors:  Evan Rosenbaum; Philip Jonsson; Kenneth Seier; Li-Xuan Qin; Ping Chi; Mark Dickson; Mrinal Gounder; Ciara Kelly; Mary L Keohan; Benjamin Nacev; Mark T A Donoghue; Sarah Chiang; Samuel Singer; Marc Ladanyi; Cristina R Antonescu; Martee L Hensley; Sujana Movva; Sandra P D'Angelo; William D Tap
Journal:  JCO Precis Oncol       Date:  2020-11-06

3.  A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases.

Authors:  David B Chapel; Aarti Sharma; Ricardo R Lastra; Livia Maccio; Emma Bragantini; Gian Franco Zannoni; Suzanne George; Bradley J Quade; Carlos Parra-Herran; Marisa R Nucci
Journal:  Mod Pathol       Date:  2022-02-04       Impact factor: 7.842

Review 4.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

5.  Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes.

Authors:  Matthew L Hemming; Changyu Fan; Chandrajit P Raut; George D Demetri; Scott A Armstrong; Ewa Sicinska; Suzanne George
Journal:  Mol Cancer Res       Date:  2020-06-09       Impact factor: 5.852

Review 6.  Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?

Authors:  Jan Philipp Novotny; Suzanne George
Journal:  Curr Treat Options Oncol       Date:  2021-09-15

7.  U2 small nuclear RNA auxiliary factor 2, transcriptionally activated by the transcription factor Dp-1/E2F transcription factor 1 complex, enhances the growth and aerobic glycolysis of leiomyosarcoma cells.

Authors:  Yuguo Li; Sihao Chen; Xin Zhang; Naiqiang Zhuo
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

8.  Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease.

Authors:  Matthew L Hemming; Kelly S Klega; Justin Rhoades; Gavin Ha; Kate E Acker; Jessica L Andersen; Edwin Thai; Anwesha Nag; Aaron R Thorner; Chandrajit P Raut; Suzanne George; Brian D Crompton
Journal:  JCO Precis Oncol       Date:  2019-01-24

Review 9.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

10.  Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib.

Authors:  Stefano Testa; Lynn Million; Teri Longacre; Nam Bui
Journal:  Case Rep Oncol       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.